Zobrazeno 1 - 10
of 311
pro vyhledávání: '"Sheila Weiss"'
Publikováno v:
In Research in Social and Administrative Pharmacy 2008 4(1):37-45
Autor:
Dan P. Zandberg, Ting-Ying Huang, Xuehua Ke, Maria R. Baer, Steven D. Gore, Sheila Weiss Smith, Amy J. Davidoff
Publikováno v:
Haematologica, Vol 98, Iss 4 (2013)
Prior studies have investigated patients' characteristics, treatments, and outcomes for older adults with myelodysplastic syndromes, but most failed to distinguish chronic myelomonocytic leukemia. Recognizing potentially important differences between
Externí odkaz:
https://doaj.org/article/8eaeb079f8b045859bcd418f971f4ec5
Autor:
Sheila Weiss Smith, Masayo Sato, Steven D. Gore, Maria R. Baer, Xuehua Ke, Diane McNally, Amy Davidoff
Publikováno v:
Haematologica, Vol 97, Iss 1 (2012)
Background There are limited reports of thrombosis among myelodysplastic syndrome patients exposed to erythropoiesis stimulating agents. It is not clear whether erythropoiesis stimulating agents are associated with an increased risk of thrombosis in
Externí odkaz:
https://doaj.org/article/be9b550903d34826a099a69b0cec09ce
Autor:
Amy J. Davidoff, Sheila Weiss Smith, Maria R. Baer, Xuehua Ke, Jason M. Bierenbaum, Franklin Hendrick, Diane L. McNally, Steven D. Gore
Publikováno v:
Haematologica, Vol 97, Iss 1 (2012)
Patient and physician characteristics associated with use of erythropoiesis-stimulating agents in myelodysplastic syndrome patients have not yet been described. Myelodysplastic syndrome patients diagnosed from 2001 to 2005 were identified from the Su
Externí odkaz:
https://doaj.org/article/083819a64ecc4ba3aa62450bf5993be3
Autor:
Whitney Neufeld-Kaiser, Daniel F. Gallego, Yajuan J. Liu, Corinne L. Fligner, Sheila Weiss, Kimberly K. Ma, Christina M. Lockwood
Publikováno v:
The Journal of Applied Laboratory Medicine. 1:576-580
A 32-year-old G3P2002 (3 pregnancies, 2 births at full term, 0 preterm, 0 abortions, 2 still living) pregnant woman of Filipino ancestry was referred to a tertiary institution for severe intrauterine growth restriction (IUGR)4 at 20 weeks' gestation.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f3d5e3a52449b2762cb9a31b6f4ae81
https://doi.org/10.1373/jalm.2016.021238
https://doi.org/10.1373/jalm.2016.021238
Autor:
Sheila Weiss Smith
Publikováno v:
New England Journal of Medicine. 357:960-963
In a 2006 report, the Institute of Medicine implored the FDA to “embrace a culture of safety” by increasing the priority accorded to the safety of patients. Sheila Weiss Smith writes that the FDA's response to the IOM report demonstrates a lack o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::101362326c039871114fa61852871c57
https://doi.org/10.1056/nejmp078157
https://doi.org/10.1056/nejmp078157
Autor:
Andrew N. Freedman, Jennifer L. Malin, Arnold L. Potosky, Behrooz K. Shamloo, Pankdeep Chhabra, Sheila Weiss Smith
Publikováno v:
Drug Safety. 35:507-518
Bevacizumab is the first in its class, vascular endothelial growth factor (VEGF) inhibitor that was initially approved by the US FDA in 2004 for the treatment of metastatic colon cancer and other solid tumors. Preapproval clinical trials, particularl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b2e5d93e93fd08c4ccfdeefa016ce34
https://doi.org/10.2165/11597600-000000000-00000
https://doi.org/10.2165/11597600-000000000-00000
Autor:
Lawrence J. Lesko, Rachel Ballard-Barbash, Robert L. Davis, Issam Zineh, Margaret R. Spitz, Christine B. Ambrosone, Nat Rothman, Sheila Weiss Smith, Lori M. Minasian, Richard M. Weinshilboum, David A. Flockhart, James H. Doroshow, Leah B. Sansbury, Heng Xie, Robert S. Epstein, Geoffrey Liu, Mary V. Relling, Richard L. Schilsky, Cornelia M. Ulrich, Stefanie A. Nelson, Howard L. McLeod, Arnold L. Potosky, Geoffrey S. Ginsburg, William D. Figg, Gurvaneet Randhawa, Muin J. Khoury, Andrew N. Freedman, Mark J. Ratain
Publikováno v:
JNCI Journal of the National Cancer Institute
Recent advances in genomic research have demonstrated a substantial role for genomic factors in predicting response to cancer therapies. Researchers in the fields of cancer pharmacogenomics and pharmacoepidemiology seek to understand why individuals
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf58427a3ed59a3e89632677d045c73b
http://europepmc.org/articles/PMC2982809
http://europepmc.org/articles/PMC2982809
Autor:
Ralph Santos-Oliveira, Marta de Souza Albernaz, Jose Augusto Bordim, Leila Jorge Antunes, Sheila Weiss Smith
Publikováno v:
Current Radiopharmaceuticalse. 3:304-307
Nuclear Medicine and with it, the production of radiopharmaceuticals, represent an increasingly important part of the global medical market. This market is estimated at over $3 billion per year and growing. In this study, we compare the current Brazi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8055d0138f0bb21e2a30a73c8daf083f
https://doi.org/10.2174/1874471011003040304
https://doi.org/10.2174/1874471011003040304
Autor:
Bradford L, Therrell, Marion, Schwartz, Carol, Southard, Donna, Williams, W Harry, Hannon, Marie Y, Mann, Sheila, Weiss
Publikováno v:
Seminars in Perinatology. 34:105-120
Newborn screening (NBS) reaches approximately all of the 4 million newborns in the United States each year and has been effective in significantly reducing the morbidity and mortality that results from certain congenital conditions. The comprehensive
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::252fe51ec97273ab8fe670f530ec07e3
https://doi.org/10.1053/j.semperi.2009.12.002
https://doi.org/10.1053/j.semperi.2009.12.002